TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Functional Evaluation of a Follow on Formula Supplemented With Lactobacillus Salivarius CECT5713
Brief Summary: The aim of the trial is to evaluate safety of a follow on formula supplemented with Lactobacillus salivarius CECT5713. A randomized double blind placebo controlled trial was carried out. Eighty six months old children were recruited by the department of pediatrics of Hospital Univeristario San Cecilio. Children were divided in two groups that consumed a follow on formula supplemented or not with the probiotic strain during 6 months. Fecal samples were obtained at the recruitment, at 3 months and at the end of the trial. In addition revision by the pediatrician was performed once a month and possible adverse effects were recorded both by the pediatrician and by parents.


Options:
A: Arm Label: Probiotic; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus fermentum | Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Follow on formula without probiotics | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus fermentum; Assigned to Arm(s): Probiotic | Intervention Type: DIETARY_SUPPLEMENT; Name: Follow on formula without probiotics; Assigned to Arm(s): Control
B: Arm Label: Bifidobacterium animalis subsp. lactis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacterium animalis subsp. lactis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacterium animalis subsp. lactis; Assigned to Arm(s): Bifidobacterium animalis subsp. lactis
C: Arm Label: A; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: follow on formula without probiotics | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: follow on formula with Lactobacillus salivarius CECT5713 | Intervention Type: DIETARY_SUPPLEMENT; Name: follow on formula without probiotics; Assigned to Arm(s): A | Intervention Type: DIETARY_SUPPLEMENT; Name: follow on formula with Lactobacillus salivarius CECT5713; Assigned to Arm(s): B
D: Intervention Type: DRUG; Name: Mixture of probiotic bacteria and prebiotic oligosaccharide; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Telephone Care Coordination for Smokers in Mental Health Clinics
Brief Summary: The purpose of this study is to evaluate whether a smoking cessation telephone care coordination program is effective and feasible in VA Mental Health Clinics.


Options:
A: Arm Label: Proactive service; Type: EXPERIMENTAL; Interventions: Behavioral: Proactive service | Arm Label: Reactive service; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Reactive service | Intervention Type: BEHAVIORAL; Name: Proactive service; Assigned to Arm(s): Proactive service | Intervention Type: BEHAVIORAL; Name: Reactive service; Assigned to Arm(s): Reactive service
B: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Other: Telephone Care Coordination | Arm Label: Arm 2; Type: EXPERIMENTAL; Interventions: Other: Telephone Care Coordination with state Quitline | Intervention Type: OTHER; Name: Telephone Care Coordination; Assigned to Arm(s): Arm 1 | Intervention Type: OTHER; Name: Telephone Care Coordination with state Quitline; Assigned to Arm(s): Arm 2
C: Arm Label: AWARD, Brief leaflet, Referral leaflet, active referral; Type: EXPERIMENTAL; Interventions: Behavioral: AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices | Arm Label: AWARD, Brief leaflet; Type: EXPERIMENTAL; Interventions: Behavioral: AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices | Arm Label: Smoking cessation booklet, general advices; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices | Intervention Type: BEHAVIORAL; Name: AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices; Assigned to Arm(s): AWARD, Brief leaflet, AWARD, Brief leaflet, Referral leaflet, active referral, Smoking cessation booklet, general advices
D: Arm Label: PA+ Smoking Cessation (LMPA); Type: EXPERIMENTAL; Interventions: Behavioral: PA+ Smoking Cessation (LMPA) | Arm Label: Standard Care Smoking Counseling (SCC); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Standard Care Smoking Counseling (SCC) | Intervention Type: BEHAVIORAL; Name: PA+ Smoking Cessation (LMPA); Assigned to Arm(s): PA+ Smoking Cessation (LMPA) | Intervention Type: BEHAVIORAL; Name: Standard Care Smoking Counseling (SCC); Assigned to Arm(s): Standard Care Smoking Counseling (SCC)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pharmacokinetics of Implanon in Obese Women
Brief Summary: Prior studies examining the pharmacokinetics, safety, and efficacy of the new etonogestrel-containing single rod implantable contraceptive device, Implanon, did not include women who exceeded 130% of ideal body weight. Yet, as these women comprise a significant portion of the U.S. population, studies of Implanon in obese women are essential. The proposed study represents an important first step in addressing the lack of data on Implanon in obese women. We aim to examine the pharmacokinetics of Implanon in obese women during the first 6 months of use and to provide data on the acceptability, side effect profile, and ease of insertion, palpation, and removal in these women. We also aim to collect samples for future validation studies of the use of the blood spot (finger-stick blood sample on filter paper) as a method of determining plasma etonogestrel.


Options:
A: Arm Label: 1; Type: N/A; Interventions: N/A | Arm Label: 2; Type: N/A; Interventions: N/A
B: Arm Label: LCS12; Type: EXPERIMENTAL; Interventions: Drug: LCS12 | Arm Label: LCS16; Type: EXPERIMENTAL; Interventions: Drug: LCS16 | Intervention Type: DRUG; Name: LCS12; Assigned to Arm(s): LCS12 | Intervention Type: DRUG; Name: LCS16; Assigned to Arm(s): LCS16
C: Arm Label: Normal weight women; Type: N/A; Interventions: N/A | Arm Label: Overweight women; Type: N/A; Interventions: N/A | Arm Label: Obese women; Type: N/A; Interventions: N/A
D: Arm Label: All participants; Type: OTHER; Interventions: Drug: All participants (Aviane) | Arm Label: Aviane and Portia; Type: ACTIVE_COMPARATOR; Interventions: Drug: Portia | Arm Label: Aviane & Aviane; Type: ACTIVE_COMPARATOR; Interventions: Drug: Aviane | Intervention Type: DRUG; Name: All participants (Aviane); Assigned to Arm(s): All participants | Intervention Type: DRUG; Name: Portia; Assigned to Arm(s): Aviane and Portia | Intervention Type: DRUG; Name: Aviane; Assigned to Arm(s): Aviane & Aviane

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-label, Observational Trial to Monitor the Incidence of Congenital Malformations in Infants of Women With an Ongoing Pregnancy After Controlled Ovarian Hyperstimulation Using Puregon® (recFSH)/Orgalutran® (Ganirelix) Followed by IVF/ICSI, or a Long Protocol With a GnRH Agonist as Historical Controls.
Brief Summary: The primary purpose of this study is to collect data on the incidence of congenital malformations in infants of women with an ongoing pregnancy after controlled ovarian stimulation with recombinant follicle stimulating hormone /ganirelix followed by in vitro fertilization (IVF) or intra cytoplasmatic sperm injection (ICSI), and to compare this incidence with that of a group of women who used a long protocol with a gonadotropin releasing hormone agonist as historical controls.


Options:
A: Arm Label: GnRH agonist; Type: EXPERIMENTAL; Interventions: Drug: Triptorelin | Arm Label: GnRH antagonist; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetrorelix | Intervention Type: DRUG; Name: Triptorelin; Assigned to Arm(s): GnRH agonist | Intervention Type: DRUG; Name: Cetrorelix; Assigned to Arm(s): GnRH antagonist
B: Arm Label: Antagonist group; Type: EXPERIMENTAL; Interventions: Other: In vitro fertilization | Arm Label: Agonist group; Type: ACTIVE_COMPARATOR; Interventions: Other: In vitro fertilization | Intervention Type: OTHER; Name: In vitro fertilization; Assigned to Arm(s): Agonist group, Antagonist group
C: Arm Label: Observational Cohort; Type: N/A; Interventions: Drug: ganirelix | Arm Label: Historical Controls; Type: N/A; Interventions: Drug: GnRH agonist | Intervention Type: DRUG; Name: ganirelix; Assigned to Arm(s): Observational Cohort | Intervention Type: DRUG; Name: GnRH agonist; Assigned to Arm(s): Historical Controls
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Patients receiving short protocol IVF/ICSI-treatment. | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Long protocol | Intervention Type: DRUG; Name: Patients receiving short protocol IVF/ICSI-treatment.; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Long protocol; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multi-Center, Continuation Trial of Belimumab (HGS1006, LymphoStat-B™), a Fully Human Monoclonal Anti-BLyS Antibody, in Subjects With Systemic Lupus Erythematosus (SLE) Who Completed the Phase 3 Protocol HGS1006-C1056 in the United States
Brief Summary: This is a continuation study to provide continuing treatment to subjects who completed study HGS1006-C1056 in the United States, to evaluate the long-term safety and efficacy of belimumab(LymphoStat-B™) in subjects with SLE disease.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Drug: Belimumab 10 mg/kg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: DRUG; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: belimumab | Arm Label: 2.; Type: EXPERIMENTAL; Interventions: Drug: belimumab | Intervention Type: DRUG; Name: belimumab; Assigned to Arm(s): 1, 2.
C: Arm Label: Belimumab 1 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 1 mg/kg | Arm Label: Belimumab 10 mg/kg; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 10 mg/kg | Intervention Type: BIOLOGICAL; Name: Belimumab 1 mg/kg; Assigned to Arm(s): Belimumab 1 mg/kg | Intervention Type: BIOLOGICAL; Name: Belimumab 10 mg/kg; Assigned to Arm(s): Belimumab 10 mg/kg
D: Arm Label: Placebo plus standard therapy; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo, Drug: Standard therapy | Arm Label: Belimumab 200 mg SC plus standard therapy; Type: EXPERIMENTAL; Interventions: Biological: Belimumab 200 mg SC, Drug: Standard therapy | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo plus standard therapy | Intervention Type: BIOLOGICAL; Name: Belimumab 200 mg SC; Assigned to Arm(s): Belimumab 200 mg SC plus standard therapy | Intervention Type: DRUG; Name: Standard therapy; Assigned to Arm(s): Belimumab 200 mg SC plus standard therapy, Placebo plus standard therapy

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sleep-directed Hypnosis As A Complement To CPT In Treating PTSD
Brief Summary: Sleep impairment is the most often reported of the 17 PTSD symptoms and is considered one of the most refractory to treatment. This study proposes the use of sleep-directed hypnotherapy to address sleep issues as a complementary element to empirically supported Cognitive Processing Therapy (CPT) in treating PTSD in sexual and physical assault survivors. Specifically the study aims to: 1) compare the results of sleep-directed hypnosis plus CPT with CPT only, 2) to assess the relationship between sleep and PTSD symptoms, 3) to examine relationships between sleep improvement, PTSD symptom improvement, and the therapeutic elements (hypnosis, exposure, cognitive therapy) to determine mechanisms of action in the intervention, 4) to assess the relationship between sleep and physical reactivity to trauma-related cues and to other stimuli.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Processing Therapy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy, Behavioral: Hypnosis | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Hypnosis; Assigned to Arm(s): 2
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: TF-CBT | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Treatment as Usual (TAU) | Intervention Type: OTHER; Name: TF-CBT; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Treatment as Usual (TAU); Assigned to Arm(s): 2
C: Arm Label: Trauma Center Trauma-Sensitive Yoga (TCTSY); Type: EXPERIMENTAL; Interventions: Behavioral: Trauma Center Trauma Sensitive Yoga Intervention (TCTSY) | Arm Label: Cognitive Processing Therapy (CPT); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Processing Therapy | Intervention Type: BEHAVIORAL; Name: Trauma Center Trauma Sensitive Yoga Intervention (TCTSY); Assigned to Arm(s): Trauma Center Trauma-Sensitive Yoga (TCTSY) | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): Cognitive Processing Therapy (CPT)
D: Arm Label: STAIR stands for Skills Training in Affective and Interpersonal Regulation; Type: EXPERIMENTAL; Interventions: Behavioral: Skills Training in Affective and Interpersonal Regulation | Arm Label: Present Centered Therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Present Centered Therapy | Intervention Type: BEHAVIORAL; Name: Skills Training in Affective and Interpersonal Regulation; Assigned to Arm(s): STAIR stands for Skills Training in Affective and Interpersonal Regulation | Intervention Type: BEHAVIORAL; Name: Present Centered Therapy; Assigned to Arm(s): Present Centered Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sleep-directed Hypnosis As A Complement To CPT In Treating PTSD
Brief Summary: Sleep impairment is the most often reported of the 17 PTSD symptoms and is considered one of the most refractory to treatment. This study proposes the use of sleep-directed hypnotherapy to address sleep issues as a complementary element to empirically supported Cognitive Processing Therapy (CPT) in treating PTSD in sexual and physical assault survivors. Specifically the study aims to: 1) compare the results of sleep-directed hypnosis plus CPT with CPT only, 2) to assess the relationship between sleep and PTSD symptoms, 3) to examine relationships between sleep improvement, PTSD symptom improvement, and the therapeutic elements (hypnosis, exposure, cognitive therapy) to determine mechanisms of action in the intervention, 4) to assess the relationship between sleep and physical reactivity to trauma-related cues and to other stimuli.


Options:
A: Arm Label: Online intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Online intervention | Arm Label: Psycho-educational website; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Psycho-educational website | Intervention Type: BEHAVIORAL; Name: Online intervention; Assigned to Arm(s): Online intervention | Intervention Type: BEHAVIORAL; Name: Psycho-educational website; Assigned to Arm(s): Psycho-educational website
B: Arm Label: Intervention arm; Type: EXPERIMENTAL; Interventions: Behavioral: The SHARE Project | Arm Label: Control arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: The SHARE Project; Assigned to Arm(s): Intervention arm
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive Processing Therapy | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: Cognitive Processing Therapy, Behavioral: Hypnosis | Intervention Type: BEHAVIORAL; Name: Cognitive Processing Therapy; Assigned to Arm(s): 1, 2 | Intervention Type: BEHAVIORAL; Name: Hypnosis; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: Behavior Therapy; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of a Low-Carbohydrate Mediterranean Diet or Low-Fat Diet in Newly-Diagnosed Type 2 Diabetic Patients
Brief Summary: The major environmental factors that increase the risk of type 2 diabetes, presumably in the setting of genetic risk, are overnutrition and a sedentary lifestyle, with consequent overweight and obesity. The high rate of weight regain has limited the role of lifestyle interventions as an effective means of controlling glycemia long term. The aims of the present study were: 1) To compare the effectiveness and safety of two nutritional protocols - namely low-carbohydrate Mediterranean diet or low-fat diet - in newly-diagnosed, drug-naive overweight patients with type 2 diabetes mellitus. The primary aim of the study was the effect on hemoglobin A1c levels; secondary aims were time to introduction of the first hypoglycemic agent, prevalence of the metabolic syndrome, percentage of patients meeting ADA goals for risk factors (HbA1c, blood pressure, LDL-cholesterol, percentage of patients with HbA1c \< 7%.


Options:
A: Intervention Type: DRUG; Name: hormone replacement therapy; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogens; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: progestins; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: estrogen replacement therapy; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: calcium; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: vitamin D; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: dietary supplements; Assigned to Arm(s): N/A
B: Arm Label: Full fat dairy group; Type: EXPERIMENTAL; Interventions: Other: Full fat dairy | Arm Label: Low fat dairy group; Type: EXPERIMENTAL; Interventions: Other: Low fat dairy | Arm Label: Control group; Type: OTHER; Interventions: Other: Control | Intervention Type: OTHER; Name: Full fat dairy; Assigned to Arm(s): Full fat dairy group | Intervention Type: OTHER; Name: Low fat dairy; Assigned to Arm(s): Low fat dairy group | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control group
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Mediterranean diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Low-fat diet | Intervention Type: OTHER; Name: Mediterranean diet; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Low-fat diet; Assigned to Arm(s): 2
D: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of a Low-Carbohydrate Mediterranean Diet or Low-Fat Diet in Newly-Diagnosed Type 2 Diabetic Patients
Brief Summary: The major environmental factors that increase the risk of type 2 diabetes, presumably in the setting of genetic risk, are overnutrition and a sedentary lifestyle, with consequent overweight and obesity. The high rate of weight regain has limited the role of lifestyle interventions as an effective means of controlling glycemia long term. The aims of the present study were: 1) To compare the effectiveness and safety of two nutritional protocols - namely low-carbohydrate Mediterranean diet or low-fat diet - in newly-diagnosed, drug-naive overweight patients with type 2 diabetes mellitus. The primary aim of the study was the effect on hemoglobin A1c levels; secondary aims were time to introduction of the first hypoglycemic agent, prevalence of the metabolic syndrome, percentage of patients meeting ADA goals for risk factors (HbA1c, blood pressure, LDL-cholesterol, percentage of patients with HbA1c \< 7%.


Options:
A: Intervention Type: BEHAVIORAL; Name: Intensive dietary advice; Assigned to Arm(s): N/A
B: Intervention Type: BEHAVIORAL; Name: Mono Unsaturated Fatty Acids in Obesity; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: diet, sodium-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, fat-restricted; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: exercise; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: diet, reducing; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: alcohol drinking; Assigned to Arm(s): N/A
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Other: Mediterranean diet | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Low-fat diet | Intervention Type: OTHER; Name: Mediterranean diet; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Low-fat diet; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III, Multi-center, Open-label, Randomized Study to Assess the Efficacy and Safety of Org 37462 Treatment in Chinese Women Undergoing Controlled Ovarian Stimulation for IVF or ICSI, Using a Long Protocol of Triptorelin as a Reference Treatment.
Brief Summary: The primary purpose of this study is to assess that ganirelix is safe and well-tolerated in Chinese women and that a controlled ovarian stimulation (COS) protocol combining recombinant follicle stimulating hormone (recFSH) with ganirelix is efficient in Chinese women undergoing COS for in vitro fertilization (IVF) or intra cytoplasmatic sperm injection (ICSI).


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: ganirelix | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: triptorelin | Intervention Type: DRUG; Name: ganirelix; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: triptorelin; Assigned to Arm(s): 2
B: Arm Label: Observational Cohort; Type: N/A; Interventions: Drug: ganirelix | Arm Label: Historical Controls; Type: N/A; Interventions: Drug: GnRH agonist | Intervention Type: DRUG; Name: ganirelix; Assigned to Arm(s): Observational Cohort | Intervention Type: DRUG; Name: GnRH agonist; Assigned to Arm(s): Historical Controls
C: Arm Label: GnRH agonist; Type: EXPERIMENTAL; Interventions: Drug: Triptorelin | Arm Label: GnRH antagonist; Type: ACTIVE_COMPARATOR; Interventions: Drug: Cetrorelix | Intervention Type: DRUG; Name: Triptorelin; Assigned to Arm(s): GnRH agonist | Intervention Type: DRUG; Name: Cetrorelix; Assigned to Arm(s): GnRH antagonist
D: Arm Label: Antagonist group; Type: EXPERIMENTAL; Interventions: Other: In vitro fertilization | Arm Label: Agonist group; Type: ACTIVE_COMPARATOR; Interventions: Other: In vitro fertilization | Intervention Type: OTHER; Name: In vitro fertilization; Assigned to Arm(s): Agonist group, Antagonist group

Answer: A